Evidence map›Paper›PMID 34318497›Full record

ArticleThe Journal of dermatology2021

Uncovering the unmet needs among psoriasis patients in the Asia-Pacific region.

Yayoi Tada, Seong Jin Jo, Yu-Huei Huang, Bryan Wahking, Bong Young Lee, Regina Gowindah, Pablo Fernández-Peñas

Abstract read
In one paragraph

Article in The Journal of dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yayoi TadaDepartment of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
Seong Jin JoDepartment of Dermatology, Seoul National University College of Medicine, Seoul, South Korea.
Yu-Huei HuangDepartment of Dermatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Bryan WahkingJanssen Asia Pacific, Singapore City, Singapore.ORCID https://orcid.org/0000-0001-6016-8209
Bong Young LeeJanssen Asia Pacific, Singapore City, Singapore.
Regina GowindahKantar Health, Singapore City, Singapore.
Pablo Fernández-PeñasSydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0003-4882-1564

Funding

Janssen Asia-Pacific
6 · The paper itself

Abstract

Studies on the psychosocial and emotional burden of psoriasis have been extensive; however, there is limited knowledge and awareness of patients' attitude and behavior towards psoriasis treatment. To understand psoriasis patients' attitude and behavior towards treatment of psoriasis, especially those treated with biologics, a multi-stage study qualitative and quantitative methodology was conducted among psoriasis patients. An online survey was conducted with 45 moderate-to-severe psoriasis patients each in Australia, Japan, South Korea, and Taiwan for 20 min. This was followed by qualitative in-depth interviews conducted among psoriasis patients in Australia (n = 3) and Japan (n = 2) for 60 min. All of the findings were workshopped with key opinion leaders and patient advisory groups to identify potential solutions addressing patients' unmet needs. Five common insights were identified across the region, highlighting patients' attitude and behavior towards psoriasis treatment, especially for those treated with biologics. These insights comprised the following: (i) one of the key factors driving patients' treatment choice included their ability to enjoy clear skin for longer period (68%); (ii) bio-maintenance patients had a higher expectation (4.9 months) of how long their skin could stay clear, compared to their pre-biologics initiation days (2.9 months); (iii) once a good response is achieved, bio-maintenance patients were more concerned about symptoms returning (44%) than development of side-effects (19%); (iv) bio-maintenance patients felt psychologically and physically affected during flare-ups despite being on more efficacious treatment; and (v) bio-maintenance patients still felt they were at risk of flare-ups (4.5/7), almost similar risk perception as non-biologics patients (4.9/7). Findings from this study showed that psoriasis patients look for treatment with the least risk of flare-ups so that they were able to enjoy clear skin for a long time.

Indexed as

Biological ProductsPsoriasisAsiaHumansSurveys and QuestionnairesTreatment OutcomeBiological Productsbiologicsflare-upspsoriasispsoriasis treatmentquality of life

Identifiers

PMID34318497
PMCPMC9290722

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.